Crizotinib-induced cardiotoxicity: The importance of a proactive monitoring and management

Alfredo Tartarone, Giuseppina Gallucci, Chiara Lazzari, Rosa Lerose, Lucia Lombardi, Michele Aieta

Research output: Contribution to journalArticlepeer-review


Crizotinib is a multitarget tyrosine kinase inhibitor and it represents the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Crizotinib is generally well tolerated and the most frequent adverse events include gastrointestinal effects, visual disorders, edema, fatigue and liver enzyme abnormalities. However, due to the increasing clinical experience with crizotinib, other toxicities are emerging, such as Q-wave T-wave interval prolongation and bradycardia. In the current review we will focus on the management of crizotinib-related cardiotoxicity.

Original languageEnglish
Pages (from-to)2043-2048
Number of pages6
JournalFuture Oncology
Issue number14
Publication statusPublished - Jul 1 2015


  • ALK-positive non-small-cell lung cancer
  • cardiotoxicity
  • crizotinib
  • drug interactions

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Crizotinib-induced cardiotoxicity: The importance of a proactive monitoring and management'. Together they form a unique fingerprint.

Cite this